Immunotherapy in breast cancer: an overview of current strategies and perspectives
/in Breast Cancer, International Publications /von 2023-02-13 / NPJ Breast Cancer 2023 Feb;9(1):7Individualized Multimodal Immunotherapy for Adults with IDH1 Wild-Type GBM: A Single Institute Experience
/in Dendritic Cells, Glioblastoma, International Publications, IOZK Veröffentlichungen /von 2023-02-13 / Cancers (Basel) 2023 Feb;15(4)Tumor cell vaccine combined with Newcastle disease virus promote immunotherapy of lung cancer
/in International Publications, Newcastle Disease Virus, NSCLC /von 2023-02-01 / J Med Virol 2023 Feb;95(2):e28554Glioblastoma treatment slowly moves towards change: novel druggable targets and translational horizons in 2022
/in Dendritic Cells, Glioblastoma, International Publications, Newcastle Disease Virus /von 2023-01-31 / Expert Opin Drug Discov 2023 Jan;Stefaan van Gool ist Herausgeber einer Sonderausgabe im Journal of Molecular Sciences
/in Brain Tumors in Children, IOZK Aktuelles, IOZK Veröffentlichungen /von IOZK[Association of autologous tumor lysate-loaded dendritic cell vaccination with extension of survival among patients with newly diagnosed and recurrent glioblastoma]
/in Dendritic Cells, Glioblastoma, International Publications /von 2023-01-20 / Strahlenther Onkol 2023 Jan;Modulated electrohyperthermia in locally advanced cervical cancer: Results of an observational study of 95 patients
/in Cervical Cancer, Hyperthermia, International Publications /von 2023-01-20 / Medicine (Baltimore) 2023 Jan;102(3):e32727Modification of Breast Cancer Milieu with Chemotherapy plus Dendritic Cell Vaccine: An Approach to Select Best Therapeutic Strategies
/in Breast Cancer, Dendritic Cells, International Publications /von 2023-01-17 / Biomedicines 2023 Jan;11(2)Current „state of the art“ on dendritic cell-based cancer vaccines in melanoma
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2023-01-09 / Curr Opin Oncol 2023 Mar;35(2):87-93
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Neue IOZK Veröffentlichung zum Thema Liquid Biopsy
- Efficacy of a Dual-Epitope Dendritic Cell Vaccine as Part of Combined Immunotherapy for HER2-Expressing Breast Tumors
- Autologous dendritic cells loaded with antigens from self-renewing autologous tumor cells as patient-specific therapeutic cancer vaccines